Seek Returns logo

SMMT vs. WAT: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at SMMT and WAT, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolSMMTWAT
Company NameSummit Therapeutics Inc.Waters Corporation
CountryUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS IndustryBiotechnologyLife Sciences Tools & Services
Market Capitalization19.51 billion USD17.79 billion USD
ExchangeNasdaqGMNYSE
Listing DateMarch 5, 2015November 17, 1995
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of SMMT and WAT by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

SMMT vs. WAT: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolSMMTWAT
5-Day Price Return3.63%0.41%
13-Week Price Return1.94%-14.21%
26-Week Price Return21.62%-20.91%
52-Week Price Return94.30%-11.05%
Month-to-Date Return-0.38%3.53%
Year-to-Date Return47.21%-19.42%
10-Day Avg. Volume3.28M0.59M
3-Month Avg. Volume4.20M0.69M
3-Month Volatility95.92%38.80%
Beta-1.191.06

Profitability

Return on Equity (TTM)

SMMT

-52.22%

Biotechnology Industry

Max
77.14%
Q3
10.76%
Median
-20.08%
Q1
-42.71%
Min
-119.20%

SMMT has a negative Return on Equity of -52.22%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

WAT

35.02%

Life Sciences Tools & Services Industry

Max
19.96%
Q3
11.55%
Median
6.22%
Q1
3.86%
Min
-6.95%

WAT’s Return on Equity of 35.02% is exceptionally high, placing it well beyond the typical range for the Life Sciences Tools & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

SMMT vs. WAT: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Net Profit Margin (TTM)

SMMT

-9,027.08%

Biotechnology Industry

Max
59.44%
Q3
16.21%
Median
-11.49%
Q1
-167.42%
Min
-409.07%

SMMT has a negative Net Profit Margin of -9,027.08%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

WAT

21.71%

Life Sciences Tools & Services Industry

Max
27.28%
Q3
16.17%
Median
7.24%
Q1
3.00%
Min
-3.05%

A Net Profit Margin of 21.71% places WAT in the upper quartile for the Life Sciences Tools & Services industry, signifying strong profitability and more effective cost management than most of its peers.

SMMT vs. WAT: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Operating Profit Margin (TTM)

SMMT

-8,108.33%

Biotechnology Industry

Max
60.62%
Q3
20.76%
Median
-12.41%
Q1
-181.14%
Min
-482.02%

SMMT has a negative Operating Profit Margin of -8,108.33%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

WAT

27.69%

Life Sciences Tools & Services Industry

Max
33.15%
Q3
19.34%
Median
13.02%
Q1
8.05%
Min
-4.38%

An Operating Profit Margin of 27.69% places WAT in the upper quartile for the Life Sciences Tools & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

SMMT vs. WAT: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Profitability at a Glance

SymbolSMMTWAT
Return on Equity (TTM)-52.22%35.02%
Return on Assets (TTM)-41.67%14.40%
Net Profit Margin (TTM)-9,027.08%21.71%
Operating Profit Margin (TTM)-8,108.33%27.69%
Gross Profit Margin (TTM)--59.02%

Financial Strength

Current Ratio (MRQ)

SMMT

5.13

Biotechnology Industry

Max
19.31
Q3
9.38
Median
4.54
Q1
2.45
Min
0.76

SMMT’s Current Ratio of 5.13 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

WAT

1.75

Life Sciences Tools & Services Industry

Max
4.76
Q3
2.77
Median
1.85
Q1
1.40
Min
0.43

WAT’s Current Ratio of 1.75 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.

SMMT vs. WAT: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

SMMT

0.00

Biotechnology Industry

Max
1.35
Q3
0.64
Median
0.09
Q1
0.00
Min
0.00

SMMT’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

WAT

0.67

Life Sciences Tools & Services Industry

Max
1.75
Q3
0.83
Median
0.41
Q1
0.18
Min
0.00

WAT’s Debt-to-Equity Ratio of 0.67 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

SMMT vs. WAT: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Interest Coverage Ratio (TTM)

SMMT

-121.35

Biotechnology Industry

Max
72.37
Q3
1.91
Median
-7.81
Q1
-63.90
Min
-153.80

SMMT has a negative Interest Coverage Ratio of -121.35. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

WAT

11.29

Life Sciences Tools & Services Industry

Max
29.61
Q3
23.24
Median
6.07
Q1
2.18
Min
-14.08

WAT’s Interest Coverage Ratio of 11.29 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.

SMMT vs. WAT: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Financial Strength at a Glance

SymbolSMMTWAT
Current Ratio (MRQ)5.131.75
Quick Ratio (MRQ)4.941.22
Debt-to-Equity Ratio (MRQ)0.000.67
Interest Coverage Ratio (TTM)-121.3511.29

Growth

Revenue Growth

SMMT vs. WAT: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

SMMT vs. WAT: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

SMMT

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SMMT currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

WAT

0.00%

Life Sciences Tools & Services Industry

Max
1.80%
Q3
0.78%
Median
0.37%
Q1
0.00%
Min
0.00%

WAT currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

SMMT vs. WAT: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Dividend Payout Ratio (TTM)

SMMT

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SMMT has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

WAT

0.00%

Life Sciences Tools & Services Industry

Max
156.00%
Q3
65.73%
Median
23.81%
Q1
0.00%
Min
0.00%

WAT has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

SMMT vs. WAT: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Dividend at a Glance

SymbolSMMTWAT
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

SMMT

--

Biotechnology Industry

Max
60.14
Q3
38.17
Median
29.01
Q1
15.12
Min
0.00

P/E Ratio data for SMMT is currently unavailable.

WAT

26.76

Life Sciences Tools & Services Industry

Max
117.96
Q3
65.59
Median
37.26
Q1
27.51
Min
1.73

In the lower quartile for the Life Sciences Tools & Services industry, WAT’s P/E Ratio of 26.76 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

SMMT vs. WAT: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Price-to-Sales Ratio (TTM)

SMMT

19,902.10

Biotechnology Industry

Max
76.98
Q3
36.53
Median
9.49
Q1
4.49
Min
0.00

With a P/S Ratio of 19,902.10, SMMT trades at a valuation that eclipses even the highest in the Biotechnology industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

WAT

5.81

Life Sciences Tools & Services Industry

Max
12.46
Q3
6.70
Median
4.24
Q1
2.68
Min
0.73

WAT’s P/S Ratio of 5.81 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

SMMT vs. WAT: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Price-to-Book Ratio (MRQ)

SMMT

60.92

Biotechnology Industry

Max
20.53
Q3
9.76
Median
4.77
Q1
2.49
Min
0.59

At 60.92, SMMT’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

WAT

9.62

Life Sciences Tools & Services Industry

Max
7.99
Q3
4.69
Median
3.30
Q1
1.88
Min
1.02

At 9.62, WAT’s P/B Ratio is at an extreme premium to the Life Sciences Tools & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

SMMT vs. WAT: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Life Sciences Tools & Services industry benchmarks.

Valuation at a Glance

SymbolSMMTWAT
Price-to-Earnings Ratio (TTM)--26.76
Price-to-Sales Ratio (TTM)19,902.105.81
Price-to-Book Ratio (MRQ)60.929.62
Price-to-Free Cash Flow Ratio (TTM)--28.57